

Case IPR2024-01312
U.S. Patent No. 11,697,028

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

BIOFRONTERA INC., BIOFRONTERA BIOSCIENCE GMBH,
BIOFRONTERA PHARMA GMBH, AND BIOFRONTERA AG
Petitioner

v.

SUN PHARMACEUTICAL INDUSTRIES, INC.,
Patent Owner

Case IPR2024-01312

U.S. Patent No. 11,697,028

PATENT OWNER'S REQUEST FOR ORAL ARGUMENT

Mail Stop Patent Board
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

Pursuant to 37 C.F.R. § 42.70(a) and the Board's February 24, 2025, Scheduling Order (Paper 10), Patent Owner Sun Pharmaceuticals Industries, Inc. ("Patent Owner") respectfully requests oral argument for the trial currently scheduled on December 3, 2025 for 60 minutes per side. Patent Owner understands that the Board is currently conducting all hearings in person. Patent Owner respectfully requests the argument to be held at the USPTO Headquarters in Alexandria, Virginia located at 600 Dulany Street, Alexandria, Virginia, 22314.

Patent Owner specifies the following issues to be argued:

- Issues related to the Board's Decision Instituting *Inter Partes* Review (Paper 9);
- Whether Claims 1, 2, 4-6, 16, 17, and 19-21 are unpatentable under 35 U.S.C. §103 as obvious over Lundahl in view of Larsen;
- Response to any issues specified by Petitioner in its Petition and Reply;
- Response to any issues specified by Petitioner in its request for oral argument;
- Any issues raised in the briefing pursuant to the schedule;
- Any issues relevant to any Orders and instructions issued by the Board;
- Any other outstanding motions and pleadings, and other issues that the Board deems necessary for issuing a Final Written Decision;
- Any differences and similarities between the arguments, evidence, and ultimate conclusions considered and determined by the ALJ in the ITC's Initial Determination in the related ITC matter (Investigation No. 337-TA-1411) and the arguments and evidence presented in IPR2024-01312; and

Case IPR2024-01312
U.S. Patent No. 11,697,028

- Any arguments presented by Petitioner and any other issues about which the Board wishes to hear arguments during oral argument.

Patent Owner also requests permission to use audio and visual equipment to display demonstratives, exhibits, and/or papers during oral argument.

Dated: October 15, 2025

Respectfully submitted,

/Yung-Hoon Ha/

Yung-Hoon Ha (Reg. No. 56,368)

yha@desmaraisllp.com

DESMARAIS LLP

230 Park Avenue

New York, NY 10169

Telephone: 212-351-3400

Facsimile: 212-351-3401

Lead Counsel for Patent Owner

Sun Pharmaceutical Industries, Inc.

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. § 42.6(e), the undersigned certifies that on October 15, 2025, a complete copy of the foregoing was served on counsel of record for Petitioner by filing this document through P-TACTS and by sending this document via electronic mail to the following addresses:

Lead Counsel	Back-up Counsel
James P. Murphy, Reg. No. 55,474 Polsinelli PC 1000 Louisiana Street, Suite 6400 Houston, Texas 77002 jpmurphy@polsinelli.com	Corey Casey, Reg. No. 66,950 Polsinelli PC 900 West 48th Place, Suite 900 Kansas City, Missouri 64112 ccasey@polsinelli.com Megan Hart, Reg. No. 79,202 Polsinelli PC 7676 Forsyth Blvd., Suite 800 St. Louis, Missouri 63105 mkhart@polsinelli.com Brian Larivee (<i>pro hac vice</i>) Polsinelli PC 100 Oliver Street, Suite 3900 Boston, MA 02110 blarivee@polsinelli.com Chad Landmon (<i>pro hac vice</i>) Polsinelli PC 1401 I St NW, Suite 800 Washington, DC 20005 clandmon@polsinelli.com

Case IPR2024-01312
U.S. Patent No. 11,697,028

Dated: October 15, 2025

Respectfully submitted,

/Yung-Hoon Ha/

Yung-Hoon Ha (Reg. No. 56,368)

yha@desmaraisllp.com

DESMARAIS LLP

230 Park Avenue

New York, NY 10169

Telephone: 212-351-3400

Facsimile: 212-351-3401

*Lead Counsel for Patent Owner
Sun Pharmaceutical Industries, Inc.*